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Thromboangiitis obliterans is a nonatherosclerotic 
inflammatory occlusive vascular disease of unknown 
origin. In the absence of smoking, other risk factors, 
such as serum lipoprotein(a), must be considered in the 
pathogenesis of this disease. 8 Even though 8 months 
after the operation the patient had returned to her 
normal activities, the prognosis will be influenced by the 
potential, and previously reported occurrence of throm- 
boangiitis obliterans in the aorta-coronary saphenous 
vein grafts. 9
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ADDITIONAL POSTBYPASS ADMINISTRATION OF TRANEXAMIC ACID REDUCES BLOOD LOSS 
AFTER CARDIAC OPERATIONS 
Junya Katoh, MD, Kouji Tsuchiya, MD, Wataru Sato, MD, Masato Nakajima, MD, and Yoshinao Iida, MD, 
Yamanashi, Japan 
Excessive bleeding after cardiac operations involving 
cardiopulmonary b pass (CPB), mostly a result of acti- 
vated fibrinolysis and platelet dysfunction, remains a 
problem. Intraoperative administration of aprotinin sig- 
nificantly decreases postbypass blood loss; however, its 
use is limited because of complications such as inadequate 
heparinization during CPB and high cost. 1 Alternatively, 
Karski and associates 2 revealed that high-dose adminis- 
tration of tranexamic acid (TA) before CPB prevents 
excessive postoperative blood loss and reduces the need 
for blood transfusions. TA inhibits fibrinolysis by binding 
to the lysine binding site on plasminogen and plasmin, 
which is the binding site for fibrin. 
It was reported that to counteract post-CPB fibrinolytic 
status and achieve hemostasis, high-dose TA administra- 
tion was needed. 3 The elimination half-life of TA is about 
80 minutes. To maintain concentrations of TA in the 
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blood during hemostasis after CPB, we gave an additional 
half of the pre-CPB dose of TA during the post-CPB 
period. The objective of this study was to investigate 
whether an additional postbypass dose of TA affects 
post-CPB blood loss after cardiac operations. 
Methods. Ninety-three patients undergoing either cor- 
onary artery bypass grafting or heart valve operation were 
studied with their informed consent. Approval for the 
study was received from our hospital's ethics review 
board. Only one cardiac surgeon (K. T.) was involved in 
the study. In this prospective, randomized trial, the pa- 
tients were divided into three groups of equal size. Patient 
characteristics are summarized in Table I. 
All patients received high-dose fentawl anesthesia. Be- 
fore CPB was established, heparin. 200 IU/kg, was given 
intravenously toeach patient. Additional heparin was added 
throughout CPB to maintain the activated clotting time at 
more than 400 seconds. Heparin was neutralized with pro- 
tamine sulfate with the use of dose-response curves. Group 
TA-1 patients received an infusion of TA. 100 mg/kg, 
intravenously, over 20 minutes oon after induction of anes- 
thesia and before CPB. Group TA-2 patients received a 100 
mg/kg dose of TA. like the group TA-1 patients, and an 
additional TA dose of 50 mg/kg infused intravenously over 
20 minutes soon after being weaned from CPB. Control 
group patients received conventional perioperative therapy. 
Red blood cells (RBCs) were transfused for a hemoglobin 
threshold of 75 gm/L or less. Mediastinal blood loss during 
the operation, but after discontinuation f CPB. and drain- 
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Table  I. Patient characteristics and surgical data 
Group 
TA-1 TA-2 Control 
(N = 31) (N - 31) (N = 31) 
Age (yr) 63.7 ± 1.5 62.9 _+ 1.7 64.7 ± 2.1 
Weight (kg) 59.1 _+ 2.6 59.7 ± 1.7 61.9 ± 1.6 
Sex 
Male 22 21 22 
Female 9 10 9 
CABG operations 21 20 19 
Valve operations 8 10 10 
Valve + CABG 2 1 2 
operations 
Preoperative Hb level 13.4 _+ 0.26 13.5 ± 0.25 13.1 ± 0.30 
(gm/L) 
CPB (rain) 79.8 _+ 3.7 79.2 ± 4.3 77.0 ± 3.8 
ACC (rain) 42.3 _+ 3.2 40.2 ± 3.8 38.8 _ 3.2 
Lowest rectal temperature 29.8 ± 0.29 30.1 ± 0.46 30.0 + 0.34 
during CPB (°C) 
Values are given as mean plus or minus the standard error of the mean. 
CABG, Coronary artery bypass grafting; Hb, hemoglobin; ACC, duration 
of aortic rossclamping. 
Table  II .  Volume of post-CPB blood loss and 
blood requirements 
Group 
TA-1 TA- 2 Control 
(N=31) (IV=31) (N=31) 
Blood loss during operation 230 ± 26.6 164 _+ 13.7 561 ± 134 
after CPB (ml)* 
Blood loss 0-6 hr (ml) 
Blood loss 6-24 hr (ml) 
Blood loss 0-24 hr (ml) 
Total blood loss (ml)? 
RBCs transfused (units) 
Postoperative Hb level 
(gm/L) 
126 ± 13.5 89.0 -+ 4.30 208 ± 30.5 
141 -+ 8.35 125 -+ 6.41 185 ± 26.2 
268 ± 18.7 214 ± 7.46 392 -+ 54.9 
497 + 33.2 378 ± 15.2 954 ± 152 
1.67 -+ 0.55 1.16 + 0.42 3.03 ± 0.82 
10.9 ± 0.17 11.6 ± 0.23 11.0 + 0.30 
Values are given as mean plus or minus the standard error of the mean. 
Hb, Hemoglobin. 
*Blood loss during operation after CPB is the volume of mediastinal blood 
loss during the operation, but after discontinuation of CPB. 
?Total blood loss is the volume of blood loss monitored from the 
discontinuation of CPB until the completion f the operation and includ- 
ing the first 24 hours after operation. 
age from mediastinal tubes for the first 24 hours after 
operation were measured. 
Data are presented as means plus or minus the standard 
error of the mean. Comparisons of the mean values in the 
three groups were computed by one- and two-way analy- 
ses of variance. 
Results. Patient characteristics were similar among 
groups, as shown in Table I. Table II summarizes the 
volume of post-CPB mediastinal blood loss, blood 
product requirements, and postoperative hemoglobin 
levels. Blood loss during the operation, but after CPB, 
in the TA-2 group was significantly lower than that in 
the TA-1 group (reduced 40%, p = 0.0238) and that in 
the control group (reduced 242%, p = 0.0047). Blood 
loss during the first 6 hours after operation was also 
significantly reduced compared with that in the TA-1 
(reduced 42%, p = 0.0050) and the control group 
(reduced 134%, p = 0.0003). Blood loss from 6 to 24 
hours in the TA-2 group was significantly lower than 
that in the control group (reduced 49%, p = 0.0298); 
however, there was no significance compared with the 
TA-1 group (p = 0.1197). 
During the first 24 hours after operation, there was a 
significant difference in blood loss in the TA-2 group 
compared with that in the TA-1 (reduced 25%, p = 
0.0052) and the control groups (reduced 83%, p = 
0.0020). Overall, the volume of blood loss monitored from 
the discontinuation of CPB until the completion of the 
operation and including the first 24 hours after the 
operation was significantly lower in the TA-2 group 
compared with that in the TA-1 group (reduced 31%,p = 
0.0009) and the control group (reduced 152%, p = 
0.0004). RBC units required for the three groups are 
compared in Table II. Three patients (9.1%) required 
RBCs in the TA-2 group whereas 4 patients (12.1%) in 
the TA-1 group and 10 patients (30.3%) in the control 
group required RBCs. The number of transfused RBC 
units in the TA-2 group was significantly ower than that in 
the control group (p = 0.0325); however, there was no 
significant difference when compared with that in the 
TA-1 group. Operative death occurred in one patient in 
the TA-1 group as a result of myocardial infarction on the 
first postoperative day. There was no occurrence of stroke, 
pulmonary embolism, or deep venous thrombosis in any of 
the patients. 
Comment. TA may improve hemostasis after operation 
by two mechanisms. First, TA inhibits post-CPB plasmin- 
induced fibrinolysis by binding to the lysine binding site on 
plasmin and plasminogen. Second, TA inhibits plasmin- 
induced platelet activation, consequently preserving platelet 
function. 4 Concentrations of the TA administered before the 
CPB period may fall to less than half of the original evel 
after CPB, because the elimination half-life of TA is about 
80 minutes. To counteract a post-CPB fibrinolytic status, 
maintenance of the concentration f TA may be important. 
Therefore we hypothesized that an additional bolus dose of 
TA given soon after CPB might prevent reactivation of 
fibrinolysis and reinforce hemostasis. 
The results proved our hypothesis was right. Blood loss 
in the TA-2 group was significantly reduced uring each of 
the tested periods except from 6 to 24 hours after the 
operation. Furthermore, our study failed to show any 
increased incidence of perioperative thrombotic ompli- 
cations. We conclude that with additional administration 
of TA after CPB, blood loss after cardiac operations 
involving CPB will be safely reduced. 
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POSTOPERATIVE RIGHT VENTRICULAR DYSFUNCTION RELATED TO AN UNEXPECTED LATE 
FATAL COMPLICATION 
Gillian A. J. Jessurun, MD, a Erwin J. A. M. G6bel, MD, ~ Nynke K. de Boer, MD, PhD, b and Jan G. Grandjean, MD, ° 
Groningen, The Netherlands 
At present, aspirin is the first-line antithrombotic herapy 
for patients after coronary artery bypass grafting. The eval- 
uation of postoperative coronary graft patency data suggests 
that dipyridamole in addition to low-dose aspirin does not 
improve aorta-coronary artery vein graft occlusion rate. 
Moreover, compared with aspirin, oral anticoagulants pro- 
vided no benefit. 1 In most clinics for heart surgery the 
antithrombotic postoperative r gimen constitutes low-dose 
aspirin at discharge. Coumarins are reserved for those 
patients with artificial valves and moderate to severe areas of 
dyskinesia or akinesia after left ventricular infarctions or 
cardiomyopathy. However, we present a pertinent clinical 
observation that should alert clinicians to the necessity of 
optimal oral anticoagulation in patients with postoperative 
transient right ventricular dysfunction or the presence of 
right-sided cardiomyopathy. 
A 41-year-old man had an anterior myocardial infarc- 
tion 6 years before admission, for which he received 
thrombolysis. This was followed by a rescue percutaneous 
transluminal coronary angioplasty of the significant resid- 
ual stenosis in the left anterior descending coronary 
artery. One year thereafter he underwent an angioplasty 
of the right coronary artery, with a second angioplasty for 
a restenosis of the right coronary artery. In June 1996 he 
was admitted with unstable angina pectoris. His chest 
symptoms remained refractory to treatment with intrave- 
nous heparin, high-dose nitroglycerin, aspirin, and a/3-ad- 
renergic blocker. Subsequently, coronary angiography re- 
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vealed slightly impaired left ventricular function with 
hypokinesis of the anterior wall. a subtotal right coronary 
artery occlusion, significant left main stenosis, an 80% 
lesion of the circumflex coronary artery, and a 70% 
stenosis of the midportion of the left anterior descending 
coronary artery. Coronary artery bypass grafting was 
performed under clinically stable conditions. The left 
thoracic artery was anastomosed to the left anterior 
descending coronary artery. The right thoracic artery was 
routed through the transverse sinus and anastomosed to
the marginal branch of the circumflex artery. The gastro- 
eplploic artery was anastomosed to the right posterior 
descending coronary artery. In addition, an endarterec- 
tomy of the right coronary artery was performed because 
of severe right ventricular dysfunction during an attempt 
to wean the patient from extracorporeal circulation. How- 
ever, after the operation the patient had a right ventricu- 
lar infarction. Volume loading and inotropic support were 
necessary to wean the patient from the ventilator. Echo- 
cardiography revealed a dilated right ventricle with se- 
verely depressed systolic function. No pericardial effusion 
and no signs of intracavitary thrombus were present. He 
had a protracted clinical recovery. One month after 
admission he was discharged in stable condition. His 
medication consisted of bumetanide, digoxin, and aspirin 
100 mg/day. 
Four weeks after discharge he was readmitted with 
severe exertional dyspnea tNew York Heart Association 
class IV}, tachypnea, nd bilateral external jugular venous 
distention but no pulmonary or peripheral edema. The 
second heart sound was loud and variably split. The 
electrocardiogram demonstrated sinus tachycardia, left 
posterior hemiblock, and an incomplete right bundle 
branch block. Findings on the chest x-ray film were within 
normal limits. Repeated echocardiography revealed a 
persistently dilated right ventricle with improved systolic 
function and no signs of a thrombotic mass. A ventilation 
perfusion scan revealed extensive mismatch in both lungs 
compatible with a high probability for pulmonary embo- 
!ism. Streptokinase was administered intravenously be- 
cause of subsequent hemodynamic deterioration as a 
